瑞普生物：获得国内首个经济动物用mRNA疫苗临床批件

Core Viewpoint - The company has received the first clinical trial approval for an mRNA vaccine for economic animals in China, marking a significant milestone in its veterinary mRNA vaccine development platform [1] Group 1: Company Developments - The company, 瑞普生物, announced that it has obtained a clinical trial approval from the Ministry of Agriculture and Rural Affairs for its mRNA vaccine targeting porcine epidemic diarrhea virus (RPS1903) [1] - This approval signifies that the company possesses a mature research and development platform for veterinary mRNA vaccines, which is expected to broaden its product line and development opportunities [1] Group 2: Industry Context - The approval of the mRNA vaccine is a pioneering step in the domestic market for economic animals, indicating a potential shift in veterinary vaccine development [1] - It is important to note that after obtaining clinical trial approval, the vaccine must complete clinical trials and submit for registration, which involves review and approval by the Ministry of Agriculture and Rural Affairs before it can be marketed [1]